Radiopharma · Q4 2026 edition available now
The Isotope Production Map: medical isotope production by producer, route and capacity
Who produces every medical radionuclide, where, by which route and at what capacity, with the source for each figure.
What you receive
- The full edition: producer tables by isotope and by country, full profiles and regional chapters
- Full profiles for Mo-99/Tc-99m, Lu-177, Tb-161 with Gd-160, Ac-225, and Pb-212 with its Th-228 feedstock
- A companion source register mapping each cited key fact to its sources and dates
- Each new quarterly edition sets out what changed, the verdict for each major isotope and the events to watch
The quarterly reference map of who produces medical radionuclides worldwide, where, by which route and at what capacity. Every capacity figure sits on one of four tiers: announced, commissioned, GMP or national approval, and actual output. An announced figure is never treated as output, and a tier with no public figure is marked as such.
The Q4 2026 edition is available now, current to 6 November 2026. The buyer summary is free to download; the full edition is licensed on quotation.
- radionuclides with named producers
- 74
- organisations
- 284
- countries
- 97
- capacity tiers, each sourced
- 4
Q4 2026 edition. Current to 6 November 2026.
Who commissions it
- Radiopharma developers qualifying a second source
- Investors and corporate development teams sizing supply risk behind a pipeline
- Isotope producers and CDMOs reading the competitive field
- Strategy and procurement teams planning around Lu-177, Ac-225, Pb-212 and Tb-161 supply
The questions it answers
- Who makes each radionuclide in clinical use or registered clinical development, and from which facilities?
- Which production routes does each producer run, and on which reactors, accelerators or generators?
- How much of the stated capacity is announced, commissioned, approved or actually delivered?
- Where does enriched target material come from, and how concentrated is it?
- What changed since the last edition, and which dated events should a supply plan watch next?
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
Questions buyers ask
- How often is the map updated?
- Quarterly. Each edition sets out what changed since the last, the verdict for each major isotope and the dated events to watch next.
- How is a capacity figure classified?
- Every figure sits on one of four tiers: announced, commissioned, GMP or national approval, and actual output. A figure an organisation gives about itself is marked as its own statement, and a figure reported only by a third party never feeds totals, rankings or charts.
- How is the full edition licensed?
- To the purchasing organisation, on quotation. Tell us who needs access and we reply within one business day.
Request a quotation
Tell us who needs access. Within one business day you have a quotation.
Other analyses
- Ac-225 Supply and Demand OutlookWhen does Ac-225 stop being scarce, and who wins when it does?
- Isotope Supply Security AssessmentOne reactor, one target, one supplier. How exposed is your programme?
- CDMO Committed Capacity AssessmentHow much CDMO capacity can you actually book, and who booked it first?
